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cal data for lung metastasis, primary and secondary liver cancer, locally advanced 
pancreatic cancer population treated with CyberKnife radiation. Searching using 
Medline, EMBASE, Cochrane Library took place in September 2013. Results: Only 
one relevant comparative clinical study (matched-pair analysis) met the inclusion 
criteria, assessing effectiveness and safety of stereotactic radiosurgery and radi-
ofrequency ablation for colorectal liver metastasis. For other neoplasms single-arm 
studies were found. Compared to RFA CyberKnife for liver metastasis was signifi-
cantly better in median local disease free survival, which was 34.4 months vs. 6.0 
months, (p< 0.001). 1 and 2-year local control rates also favored CK (85.0% vs. 65.0% 
and 80.0% vs. 61.0%, respectively) but the difference wasn’t significant. However, 
trend for better OS was found with RFA (34.4 vs. 52.3 months). For lung metastasis, 
treatment with CK resulted in 24.0-62.0% complete or partial response, 38.0-76.0% 
patients stabilized. In primary liver tumors OR (CR + PR) was observed in 63.0-86.0% 
patients, 0.0-29.0% stabilized, median PFS reached 10.0-15.8 months. Inconsistent 
results were seen in locally advanced pancreatic cancer population. In one study 
92.0% responded or stabilized but in other only 1 patient of 77 had PR. Median OS 
was 6.4-10.3 months. All studies reported mostly mild adverse events after CK. 
Serious AE were rare. ConClusions: There is limited quality evidence on the 
effectiveness and safety of robotic image-guided stereotactic radiosurgery in 
patients with soft tissue neoplasms. Available studies are highly heterogenic in 
methods, patients characteristics and outcomes but suggest that CyberKnife may 
be beneficial in local tumor control. There is a need of well-designed comparative 
studies.
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objeCtives: For patients with relapsed or refractory (R/R) chronic lymphocytic 
leukemia (CLL), treatment outcomes are poor and treatment options are limited. 
Ibrutinib is an oral, once-a-day, first-in-class covalent inhibitor of Bruton’s tyrosine 
kinase approved by the Food and Drug Administration (FDA) for R/R CLL. In a recent 
phase III trial (PCYC-1112), ibrutinib was associated with improved progression-free 
survival (PFS, hazard ratio [HR] = 0.215) and overall survival (OS, HR= 0.387) versus 
ofatumumab. The aim of this study is to provide a summary and analysis of results 
observed with current therapies in high-risk patients with R/R CLL. Methods: 
A systematic literature review and targeted literature search of clinical trials and 
international treatment guidelines in PubMed/MEDLINE (January 1,2001–April 
28,2013) and ASCO/ASH/EHA conference proceedings (2011–2013) were conducted 
to identify and evaluate current treatment options for R/R CLL, including alem-
tuzumab, rituximab, bendamustine, chlorambucil, and ofatumumab. Results: 
Study results highlight poor outcomes with existing treatment options and 
continuously high unmet need in patients. Sixteen trials were identified; the 
majorities were single-arm with small sample sizes, making comparative effec-
tiveness difficult to establish. Time-to-treatment failure was 5.8 months with 
alemtuzumab, while median PFS was 5.5 months with rituximab, 5.5–5.7 months 
with ofatumumab, 8 months with chlorambucil-ritiximab, and 15.2 months in 
previously-treated patients and 6.8 months in previously-treated patients with 
del (17p) with bendamustine-rituximab. Ofatumumab has demonstrated activ-
ity in patients with difficult-to-treat, high-risk CLL and is the only recognized 
and approved treatment by health authorities globally in this treatment setting 
and recommended in treatment guidelines. ConClusions: The lack of standard 
of care creates challenges for defining comparators in clinical trials and health 
technology assessments. In R/R CLL with high-risk features, ofatumumab is an 
appropriate comparator. Interim results from the phase III RESONATE trial showed 
that ibrutinib achieved significantly improved efficacy versus ofatumumab, even 
in high-risk disease patients.
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objeCtives: MTC is a rare form of thyroid cancer with prevalence of less than 7 per 
100,000. A majority of MTC patients have RET mutations, and RET M918T mutations 
are associated with especially poor prognosis. In 2012, EMA approved the first tyros-
ine kinase inhibitor (TKI) CAPRELSA® (vandetanib, VDB) for the treatment of MTC. 
In March 2014, the EMA approved another TKI -COMETRIQ® (cabozantinib, CBZ) for 
the treatment of adult patients with progressive, unresectable locally advanced or 
metastatic MTC, with orphan drug status. The objective of this study was to assess the 
relative efficacy in PFS and OS of CBZ vs VDB. Methods: Since there are no clinical 
trials directly comparing the two treatments, an adjusted indirect comparison (Bucher 
et al. method) was used. Evidence on PFS for the two treatments was collected from 
the pivotal clinical trials in MTC. The analysis considered all patients and a subgroup 
of RET M918T mutation positive (RET+) patients. Our analysis focused on PFS due 
to lack of evidence for the VDB OS in the RET M918T mutation subgroup. In the all 
patients analysis three different scenarios were explored: a logrank model to ensure 
comparability with the VDB data; a Cox model stratified on age at randomization and 
prior TKI status; and a Cox model without stratifications. Results: In the subgroup 
analysis (logrank model) PFS was estimated to increase by 65% with CBZ comparing 
to VDB (HR 0.35; 95% CI 0.14-0.87). In the all-patients analysis the estimates were less 
conclusive: logrank model (HR 0.72; 0.40-1.28), Cox model with stratifications (HR 0.61; 
0.35-1.04), Cox model without stratifications (HR 0.66; 0.39-1.13). ConClusions: The 
results showed a positive trend in favour of CBZ in PFS. Given the limited evidence a 
direct head-to-head comparison is necessary to validate the study findings.
K-M graphs. ConClusions: Due to very limited availability of trials with robust 
endpoints and long-term follow-up, alternative options for establishing compara-
tive efficacy must be used for decision making in relapsed or refractory MCL. These 
alternatives include implementing comparisons of single-arm trial data without 
adjustment (i.e., via naïve comparison) or methods such as match-adjusted indi-
rect comparison (MAIC) to derive comparative estimates. MAIC is a relatively novel 
method and may be difficult to implement given the heterogeneity in trial designs 
and patient-level characteristics in MCL trials. The scarcity of K-M data to inform 
PFS and OS of certain comparators further limits the comparisons that can be made 
through modeling.
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objeCtives: The prognosis of patients with metastatic cervical cancer (CC) remains 
poor, and treatment options are limited, with no single agent or combination of 
agents recognised as standard of care; cisplatin/paclitaxel is the therapy most cited 
by guidelines. This study aimed to assess the efficacy of reported treatment options 
for patients with metastatic CC. Methods: Searches of PubMed were conducted, 
with no date restrictions, to identify published randomised controlled Phase II/III 
clinical trials (RCTs) of chemotherapies recommended by treatment guidelines, 
and radiotherapy and/or surgery, that reported overall survival (OS) in patients with 
metastatic (systemic recurrent, persistent or de novo-metastatic) CC. Treatment 
guidelines and the Cochrane Library were also explored to identify additional cita-
tions. Results: Of 65 articles identified, 10 articles published between 1987 and 
2014 proceeded to data extraction. Evidence supporting the use of chemotherapy 
was limited to cisplatin-monotherapy or platinum-based combination therapy. 
Overall the OS benefit of these agents ranged from 0.9 to 2.9 months and 0.79 to 
1.32 for hazard ratio (HR). The latest innovation, bevacizumab plus chemotherapy, 
demonstrated the greatest significant gain in OS versus chemotherapy (OS gain 
3.7 months; HR 0.71; p= 0.004). The study did not identify any RCTs that supported 
the use of surgery and/or radiotherapy in this setting; the evidence was limited to 
seven retrospective hospital based studies. ConClusions: This study highlighted 
an unmet need for additional treatment options for metastatic CC. Use of cispl-
atin-monotherapy or platinum-based combination therapy has provided limited 
survival benefits for many decades. The novel combination of bevacizumab plus 
chemotherapy has demonstrated an increase in survival in these patients. However, 
since there is no RCT evidence supporting the use of surgery and/or radiotherapy, 
a health technology appraisal of these alternative interventions is not currently 
feasible. Additional clinical research is urgently needed to assess the comparative 
clinical value of these therapies.
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objeCtives: Abiraterone acetate plus predniso(lo)ne (AA) and enzalutamide (E) 
are novel therapies for the treatment of metastatic castration-resistant prostate 
cancer in chemotherapy naïve patients. Pivotal trials have been conducted evalu-
ating the efficacy of the drugs using different comparators. In the COU-AA-302 
trial, patients were randomised between AA and active comparator predniso(lo)
ne whereas in the PREVAIL trial, E was compared against placebo. For health 
economic purposes, the mean overall survival (OS) and radiographic progression-
free survival (rPFS) of both novel agents need to be compared in the absence 
of head-to-head trial data. Methods: Due to the difference in the comparator 
arms, only survival data from AA and E were used for the comparison. Observed 
individual level survival data with baseline patient characteristics were available 
for AA. Individual survival data were simulated for E to replicate the rPFS and OS 
curves published for the pivotal trial. rPFS and OS were modeled and extrapolated 
by fitting parametric survival functions. The Weibull, exponential, and lognor-
mal models were evaluated based on statistical and clinical considerations, i.e. 
assessing the model fit and the implied hazard profiles, respectively. To control 
for differences in baseline patient characteristics (PSA, ECOG, Gleason score, BPI, 
LDH, metastasis, age, race) rPFS and OS estimates for AA were adjusted using a 
matching algorithm. Results: The Weibull models were selected for extrapo-
lation of both OS and rPFS. The mean rPFS was estimated to be 23.9 (95% CI: 
21.5-26.3) and 19.5 (95% CI: 16.0-23.9) months for AA and E respectively. Mean OS 
was estimated to be 38.7 (95% CI: 36.4-40.7) and 34.6 (95% CI: 31.8-37.8) months 
respectively. ConClusions: Based on currently available data and the presented 
modeling approach, these findings suggest that AA is associated with longer mean 
rPFS and OS than E.
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CliNiCAl effeCTiVeNess of roboTiC imAge-guided sTereoTACTiC 
rAdiosurgery (CyberkNife) iN seleCTed PrimAry ANd seCoNdAry sofT 
Tissue NeoPlAsms: A sysTemATiC reView
Wlodarczyk A., Ceglowska U., Slomka M., Luchowska K.
Agency for Health Technology Assessment In Poland (AHTAPol), Warsaw, Poland
objeCtives: Effectiveness of radiosurgery for head and spinal neoplasms is 
established. The aim of this study was to systematically review the clinical lit-
erature of CyberKnife for people with selected primary and secondary soft tissue 
lesions. Methods: A systematic search was conducted for best available clini-
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vs. MPT via MP showed a statistically not significant advantage for VMP regarding 
survival outcomes. Significant benefits were observed for CR and development of 
any grade 3-4 AEs favouring VMP. ConClusions: Analysis of both aggregated and 
individual patient data essentially lead to the same conclusions, i.e. VMP and MPT 
seem more effective than MP, VMP seems ahead of MPT regarding response criteria 
and adverse events. We found significant between-trials heterogeneity, however 
no consistent relationship of effect and study-level covariates (e.g. maintenance 
dosing) was apparent. Thus, we relied on the random effects approach to meta-
analysis to cope with the unexplained trial-to-trial variability. Our results may best 
be confirmed by a head-to-head trial of VMP vs. MPT.
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objeCtives: A health technology assessment (HTA) informing the recent NICE 
guidance regarding the use of erythropoiesis-stimulating agents (ESA) in cancer-
treatment induced anaemia (CIA) identified uncertainty around the overall survival 
hazard ratio (OSHR). We investigated how the understanding of OS in CIA patients 
treated with ESAs has shaped over time and the effects of accumulating OS evidence 
on cost-effectiveness. In addition, the effects of narrowing inclusion criteria, by com-
paring the HTA results to a recent Cochrane review, were investigated. Methods: 
CMA was applied to both HTA review and Cochrane review OS data to identify pat-
terns in results; study results were accumulated by the year of publication. Annual 
OSHR results from the CMA were applied to an economic model developed in the 
HTA to calculate the cost-effectiveness of ESAs. Results: Precision of the OSHR 
estimate appeared to improve with additional evidence, but the true location of the 
estimate remained uncertain and the best estimate varied over time. Using the HTA 
CMA, results from 2001 and 2002 suggested survival benefits to using ESAs (0.77, 95% 
CI 0.60–0.98 and 0.78, 95% CI 0.65–0.93 respectively), with ESAs being cost-effective 
at a willingness to pay threshold of £30,000 per QALY for all values of the OSHR 95% 
CI. HTA CMA for all other years and all Cochrane CMA results did not suggest any 
significant effects of ESAs on OS. Cost-effectiveness results were therefore uncer-
tain. ConClusions: Current evidence suggests we cannot reject the possibility 
of no difference in OS between patients receiving or not receiving ESAs, regardless 
of study inclusion criteria. However, there is also insufficient evidence to support 
such conclusions, particularly as earlier results from narrower inclusion criteria sug-
gested some survival benefits. This analysis highlights the additional uncertainty of 
the current evidence base on cost-effectiveness analyses, which cannot be captured 
in standard sensitivity analyses.
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borTezomib re-TreATmeNT iN PATieNTs wiTh mulTiPle myelomA (mm). 
A reAl world mediCAl PrACTiCe exPerieNCe from A swedish NATioNAl 
regisTry
Thilakarathne P.1, Diels J.2, van Sanden S.3, Liwing J.4, Chirita O.5, Van Agthoven M.6, Nahi H.7
1Janssen Pharmaceutica N.V., Beerse, Belgium, 2Janssen Research & Development, Beerse, Belgium, 
3EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium, 4Janssen-Cilag AB, Sollentuna, 
Sweden, 5Janssen, High Wycombe, UK, 6Janssen-Cilag BV, Tilburg, The Netherlands, 7Karolinska 
University Hospital, Solna, Sweden
objeCtives: The question of sequencing multiple myeloma (MM) treatments is a 
key one, as is the retreatment in patients where the same treatment was effective 
in earlier lines. We investigated bortezomib retreatment in a Swedish MM national 
registry. Methods: Patients diagnosed with MM since January 2000 until June 2011 
from 7 university clinics, 5 regional centers and 3 local hospitals in Sweden were 
included. Time to response and overall survival (OS) were analyzed using stratified 
Kaplan-Meier analysis. Results: Of the 541 patients treated with bortezomib (out 
of a total population of n= 1638), 93 were retreated with bortezomib. Median follow-
up from start of retreatment was 10.2 mos. Median age was 63.5 (range 38–83), 57.3% 
were male, 34.2%/15.9%/20.7% had stage I/II/III disease (ISS); median number of 
prior therapies at initial bortezomib and retreatment was 1 and 3. 26.8%/32.9% of 
pts initiated retreatment as 3rd/4th line therapy. 37.8%/22.0% initiated bortezomib 
retreatment in combination with dexamethasone, 7.3% in monotherapy, compared 
to 40.3%, 21.8% and 8.5%, at initial bortezomib. ≥ PR/VGPR-rates at re-treatment were 
59.1%/12.7%, compared to 82.0%/39.9% at initial bortezomib. Median time to ≥ PR/
VGPR was 2.4/1.3 months at retreatment versus 1.9/2.1 at initial bortezomib. The 
≥ PR rate at retreatment was numerically longer in patients with < = 2 (75.1%) vs > = 3 
(20%) therapies prior to retreatment. Median PFS/OS from start of re-treatment was 
5.5 [95%CI: 3.7, 10.0]/17.4 [10.3, 26] months, compared to 8.1 [6.9, 9.7]/25.9 months 
[21.0, 31.6] for initial bortezomib. Number of prior therapies at retreatment did not 
affect PFS; however, OS was longer in pts with fewer prior therapies (p= 0.0112). 
There was a trend towards longer PFS (p= 0.087) in retreated patients who achieved 
> = PR compared to non-responders. ConClusions: These data suggest that, in 
everyday medical practice, bortezomib retreatment is effective in relapsed/refrac-
tory MM, with more than half of pts who responded to initial bortezomib achieving 
≥ PR at retreatment.
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objeCtives: The aim was at assembling published evidence on treatments for RAS 
wild-type (wt) (KRAS and NRAS exon 2,3,4) metastatic colorectal cancer (mCRC) 
to evaluate the efficacy and safety of cetuximab in combination with FOLFOX or 
FOLFIRI chemotherapy as first line treatment of these patients. The outcomes of 
interest were progression free survival (PFS), overall survival (OS), overall response 
(ORR), and adverse event data. Methods: A systematic literature search was per-
formed on the 24th March 2014 in Medline, Embase, and The Cochrane Library to 
identify all randomized controlled trials (RCTs) as well as single arm trials concern-
ing the efficacy and safety of first line interventions of interest in patients with 
RAS wt mCRC. Abstract and article selection was performed by two independent 
researchers, with a third person resolving disagreements, according to predefined 
standards, which were based on criteria for patient, intervention, comparator, 
outcomes and study design (PICOS). Results: 596 citations were identified after 
removing duplicates. 520 citations were excluded for reasons including: patient 
population (231), study design (174), intervention (74), outcomes (23) and duplicates 
(18). A total of 76 abstracts were included and the full-text version of these publica-
tions were retrieved and screened resulting in excluding 69 further publications due 
to the study design (20), patient population (43), outcomes (5), and one (1) duplicate, 
not being in line with the review selection criteria. Ten citations on five different 
RCTs were identified that met the inclusion criteria. ConClusions: This system-
atic review provided the latest studies on RAS wild-type (wt) metastatic colorectal 
cancer (mCRC) treatments. Despite the small number of studies available for a 
relatively new biomarker-specific mCRC, anti- EGFR treatments such as cetuximab 
in combination with FOLFOX and FOLFIRI have demonstrated a significant benefit 
in progression free survival (PFS), overall survival (OS) and overall response rate 
(ORR) versus chemotherapy alone in mCRC RAS wt patients.
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objeCtives: Malignant pleural mesothelioma (MPM) is a rare tumour with a poor 
survival and prognosis. In Russia, the epidemiology of this disease has not been well 
studied. We conducted an epidemiological study to understand the characteristics of 
patients with MPM in Russia. Methods: Retrospective study of the characteristics 
of patients with MPM. Patients treated for 1st and 2ndline therapy were included 
in ten centers of the Russian Federation. The data were generated from hospital 
records, electronic databases, and other sources of information between June and 
December in 2013. Results: One hundred and twelve patients were enrolled. The 
average age was 60.0±10.87 years and 42% were women. Harmful work environ-
ment was indicated in 21/112 (18.8%) of the patients. The exposure to asbestos was 
reported in 10/112 (8.9%) patients, and contact with erionite in 8/112 (7.1%) patients. 
Fifty percent (56/112) of the patients were smokers or are current smokers; smoking 
period was 25.3±13.25 years. The disease stage at diagnosis was I-II in 31 (27.6%), 
III-IV in 81 (72.4 %) patients. The ECOG performance status was 0 in 16 (14.3%), 
1 in 46 (41.1%), 2 in 30 (26.8%), 3 in 15 (13.4%) and 4 in 1 (0.9%) patients, in 4 patients 
- unknown. 50/112 (44.6%) patients had immunohistochemical verification of the 
diagnosis. Antineoplastic drugs were used to treat 85/112 (75.9%) patients. The main 
drugs used were cisplatin (n= 75), gemcitabine (32), doxorubicin (34), pemetrexed 
(29) and carboplatin (21). ConClusions: In Russia, the majority of MPM patients 
were diagnosed at advanced stages of disease. In 80% of the cases, a harmful work 
environment was not identified. Given the low prevalence and the frequent use 
of off-label medicines, it can be considered an orphan disease. Limitations: Only 
limited number of centres was included.
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objeCtives: Motivated by the discussion whether the german AMNOG is applied 
to currently marketed drugs we compared first-line therapies for patients with 
multiple myeloma (MM). Methods: A systematic literature search for randomized 
controlled trials (RCTs) was conducted and VMP (bortezomib (Velcade), melphalan 
and prednisone), MPT (melphalan, prednisone and thalidomide) and MP (melpha-
lan and prednisone) were identified as therapies of interest. We extracted infor-
mation on overall survival (OS), progression-free survival (PFS), response criteria 
(CR, VGPR, PR), and grade 3-4 AEs (any, hematological, non-hematological, DVT, 
PNP). Random-effects meta-analysis was used for direct and the Bucher method 
for adjusted indirect treatment comparison. Results: Seven RCTs with a total of 
2,367 patients were included in our analyses, one RCT (n= 682) comparing VMP vs. 
MP and six RCTs (n= 1,685) comparing MPT vs. MP. Direct head-to-head comparison 
of  VMP vs. MPT was lacking. For MPT vs. MP, data were extracted from a recently 
published meta-analysis of individual patient data if available. VMP was superior to 
MP regarding OS. Both VMP and MPT were superior to MP regarding PFS and response 
criteria, but had a higher risk of developing AEs. The indirect comparison of VMP 
